Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
Condition(s):Primary Hyperparathyroidism; Parathyroid Adenoma; Parathyroid HyperplasiaLast Updated:May 25, 2021Completed
Hide Studies Not Open or Pending
Condition(s):Primary Hyperparathyroidism; Parathyroid Adenoma; Parathyroid HyperplasiaLast Updated:May 25, 2021Completed
Condition(s):Chronic Kidney Failure; Secondary HyperparathyroidismLast Updated:March 27, 2012Completed
Condition(s):Vitamin D Deficiency; Primary Hyperparathyroidism; HypercalcemiaLast Updated:November 18, 2013Completed
Condition(s):Secondary Hyperparathyroidism; HemodialysisLast Updated:June 6, 2013Completed
Condition(s):Secondary Hyperparathyroidism; Chronic Kidney DiseaseLast Updated:March 31, 2022Recruiting
Condition(s):Parathyroid Carcinoma; Primary HyperparathyroidismLast Updated:May 27, 2021Completed
Condition(s):Secondary Hyperparathyroidism; Chronic Kidney DiseaseLast Updated:April 30, 2021Completed
Condition(s):Primary HyperparathyroidismLast Updated:July 3, 2018Completed
Condition(s):Hyperparathyroidism; Hypercalcemia; Parathyroid Neoplasm; Multiple Endocrine Neoplasia; MEN1Last Updated:February 28, 2022Completed
Condition(s):Secondary Hyperparathyroidism; End Stage Renal Disease; Parathyroid HyperplasiaLast Updated:May 6, 2014Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.